NCT07318415 A Study of Multiparametric Ultrasound Imaging (mpUS) for People With Endometrial Cancer
| NCT ID | NCT07318415 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Memorial Sloan Kettering Cancer Center |
| Condition | Endometrial Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2025-12-11 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2025-12-11 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The researchers are doing this study to see how well multiparametric ultrasound (mpUS) imaging can evaluate vaginal tissue before and after IVRT. IVRT is routinely used to treat endometrial cancer but can cause damage to the vaginal tissue (vaginal toxicity). Side effects of vaginal toxicity can include vaginal dryness, itching, soreness, discharge, narrowing or shortening of the vagina (stenosis), and vaginal fibrosis (hardening), which can affect sexual function. The researchers will also look at whether participants are able to complete (tolerate) all mpUS imaging for this study.
Eligibility Criteria
Inclusion Criteria: * Patients must be diagnosed with a primary endometrial carcinoma. The following histologic subtypes are eligible for inclusion: endometrioid, serious, clear cell, dedifferentiated/undifferentiated, mixed epithelial, adenocarcinoma not otherwise specified, and carcinosarcoma * Initial surgical treatment must have included hysterectomy, bilateral salpingo-oophorectomy, and pelvic lymph node assessment with either sentinel lymph node mapping/sampling or pelvic lymph node dissection. Surgical assessment of the para-aortic lymph nodes is not required * Patients must have had a complete surgical resection with negative margins and no residual gross disease after surgery * Patients must have FIGO (2009) stage I-II disease (per surgical staging) * Age ≥ 18 years * Patients must be able to start radiotherapy within 12 weeks from date of surgery Exclusion Criteria: * Patients receiving chemotherapy or hormonal therapy * A prior or concurrent malignancy whose natural history or treatment would interfere with the toxicity or efficacy assessment of IVRT * Prior pelvic radiotherapy * Active genitourinary infection requiring antibiotics, except for uncomplicated urinary tract infection * History of active inflammatory bowel disease requiring treatment, including Crohn's disease and ulcerative colitis * Concurrent psychiatric or medical condition or disease which, per investigator judgement, would make them unsuitable candidates for study enrollment
Contact & Investigator
Kaled Alektiar, MD
PRINCIPAL INVESTIGATOR
Memorial Sloan Kettering Cancer Center
Frequently Asked Questions
Who can join the NCT07318415 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Endometrial Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07318415 currently recruiting?
Yes, NCT07318415 is actively recruiting participants. Contact the research team at alektiak@mskcc.org for enrollment information.
Where is the NCT07318415 trial being conducted?
This trial is being conducted at Basking Ridge, United States, Middletown, United States, Montvale, United States, Commack, United States and 3 additional locations.
Who is sponsoring the NCT07318415 clinical trial?
NCT07318415 is sponsored by Memorial Sloan Kettering Cancer Center. The principal investigator is Kaled Alektiar, MD at Memorial Sloan Kettering Cancer Center. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.